	US 11,752,135 B2
	Liquid pharmaceutical formulation
Andreas Schuetz, Martinsried (DE); and Klaus Hellerbrand, Martinsried (DE)
Assigned to PROJECT PHARMACEUTICS GMBH, Martinsried (DE)
Appl. No. 17/42,795
Filed by Project Pharmaceutics GmbH, Martinsried (DE)
PCT Filed Mar. 29, 2019, PCT No. PCT/EP2019/057984 § 371(c)(1), (2) Date Sep. 28, 2020, PCT Pub. No. WO2019/185859, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 100750 (LU), filed on Mar. 29, 2018.
Prior Publication US 2021/0023059 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01); A61K 31/192 (2006.01); A61K 47/02 (2006.01); A61K 47/34 (2017.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01)

CPC A61K 31/4184 (2013.01) [A61K 31/192 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 47/02 (2013.01); A61K 47/34 (2013.01)]

16 Claims

1. A liquid pharmaceutical formulation, having a water content of below 1.0% (w/w) water, comprising

a) Bendamustine as an active pharmaceutical ingredient;

b) at least one pharmaceutically acceptable organic solvent comprising propylene glycol, polyethylene glycol 400 (PEG 400) or a mixture of propylene glycol and PEG 400; and

c) a calcium salt.